



**1st MEETING OF THE EUROPEAN SOCIETY  
FOR IMPOTENCE RESEARCH (ESIR)**

**September 13-16, 1995**

*Venue : Porto Carras, Chalkidiki, Greece*


**FINAL PROGRAM**

*"It is evident that by the efflux from heart and liver, the air of the lungs comes to the body of the penis and provokes an erection"*

**Aristotle (384-322 BC)**

*"Veins and nerves from all over the body come together in the genitals; as they rubbed and warmed, they swell up and a kind of irresistible itching feeling is created, bringing great pleasure and warmth to the whole body, Once the sperm has arrived in the spinal marrow, it travels down through the kidneys (...) and reaches the male copulatory member through the testicles, not by the same duct as our urine, but by its own particular parallel channel."*

**Hippocrates (460-377 BC)**



**1st MEETING OF THE EUROPEAN SOCIETY  
FOR IMPOTENCE RESEARCH (ESIR)**

In collaboration with  
the Department of Urology,  
Aristotle University of Thessaloniki, Greece

Under the auspices of :  
International Society for Impotence Research (ISIR)  
Aristotle University of Thessaloniki, Greece  
Ministry of Macedonia and Thrace

**FINAL PROGRAM**

## **WELCOME FROM ESIR**

The European Society for Impotence Research (ESIR) was initiated in 1994, at the meeting of the International Society for Impotence Research (ISIR) as a regional European chapter of ISIR.

Europe is conceived as the countries belonging to the European region of the World Health Organization which at the moment consists of a total of 51 countries.

It has been the intention of the organizing committee to create a firm contact and inspire as many colleagues as possible from the former Eastern European countries to participate in the activities of ESIR.

It was a great pleasure to accept the invitation from Dr. Dimitrios Hatzichristou to organize the first meeting of the society. With a warm back up of the Aristotle University of Thessaloniki and the Department of Urology, he and his associates have worked extremely hard to create the frame for the scientific content which the participants shall present and discuss during the days to follow. For this work we are grateful and now is the time for a fruitful meeting which hopefully shall benefit our patients.

A warm welcome to all.

Gorm Wagner  
Chairman, ESIR

# THURSDAY, SEPTEMBER 14, 1995

10:00-12:30 Podium I: Pharmacology

10:00 -11:15 Section A: Clinical Pharmacology

**Moderators: J. Buvat (France) - H. Knispel (Germany)**

- 01** Quality of life effects of alprostadil therapy for erectile dysfunction  
*Glick H.A., McCarron T.J., Willke R.J., Erder M.H., Althof S.E., Linet O.I.(U.S.A.)*
- 02** Long-term use of vasopatin in the treatment of erectile dysfunction  
*Gerstenberg T. (Denmark)*
- 03** Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in human cavernous smooth muscle: characterization and functional effects of PDE-inhibitors in vitro and in vivo  
*Stief C.G., Ückert S., Truss M.C., Becker A.J., Taher A., Jonas U. (Germany)*
- 04** Corporal response to intra-spongiosal injection of vasoactive drugs  
*Vardi Y. (Israel)*
- 05** Reduction of pain with intra-urethral prostaglandin for erectile dysfunction  
*Schmidt A.C., Chatteraj S.C., Kanfer I. (South Africa)*
- 06** Clinical and hemodynamic effects of transdermal alprostadil for mild arteriogenic impotence: a double-blind placebo-controlled study  
*Montorsi F., Guazzoni G., Barbieri L., Rigatti P., Iannaccone S., Santus A., Sartani A. (Italy)*

11:15-12:30 Section B: Basic Pharmacology

**Moderators: H. Hedlund (Sweden) - F. Giuliano (France)**

- 07** Facilitatory effect of moxisylyte (ERECNOS) on erection in rats  
*Bernabé J., Rampin O., Giuliano F., Riffaud J.P., Jardin A. (France)*
- 08** Mechanisms of NO-induced relaxation of rabbit corpus cavernosum smooth muscle  
*Schmidt P., Gupta S., Daley J.T., Saenz de Tejada I., Jünemann K.P. (Germany - U.S.A.)*
- 09** Relaxant effects of phosphodiesterase (PDE) inhibitors on rabbit cavernosum smooth muscle  
*Knispel H.H., Gerhardus R., Beckmann R., Miller K. (Germany)*
- 010** Differential relaxation of human corpus cavernosum smooth muscle by potassium (K) channel openers: evidence that relaxation is both agonist dependent and altered by diabetes mellitus  
*Giraldi A., Zhao W., Gondre M., Murray F., Christ G.J. (U.S.A.)*
- 011** Comparative activities of calcium-dependent ATPase between rabbit corpus cavernosum and urinary bladder smooth muscle  
*Levin R.M., Gong C., Broderick G.A. (U.S.A.)*
- 012** An inwardly rectifying current in cultured human corpus cavernosum endothelial cells  
*Beekman R., Walsh I., Lycklama à Nijeholt A.A.B., Marani E., Kropman R.F. (The Netherlands)*

## THURSDAY, SEPTEMBER 14, 1995

14:00-15:30 Podium II: Physiology - Pathophysiology

Moderators: P. Metz (Denmark) - F. Pesce (Italy)

- 013** Functional effects mediated by the L-arginine/nitric oxide pathway in the human corpus spongiosum  
*Hedlund P., Larsson B., Alm P., Andersson K.E. (Sweden)*
- 014** Lack of corpus cavernosum nitric oxide synthase immunoreactivity in men undergoing gender reassignment  
*Pickard R., Davenport A., Powell P. (U.K.)*
- 015** Are the metabolic changes during pharmacological or mechanical erection similar to physiological erection?  
*Caufriez M., Sattar A.A., Bilene C., Schulman C.C., Wespes E. (Belgium)*
- 016** Oxytocinergic innervation of the sacral parasympathetic nucleus in the male rat  
*Tang Y., Giuliano F., Rampin O., Rousseau J.P., Calas A. (France)*
- 017** Primary erectile dysfunction: an unresolved clinical problem  
*Lehmann K., Schöpke W., Hauri D. (Switzerland)*
- 018** Nocturnal autonomic function in sleep-related painful erections  
*Ferini-Strambi L., Montorsi F., Zucconi M., Oldani A., Smirne S., Rigatti P. (Italy)*
- 019** Testicular cancer and sexual dysfunctions: the patient's needs  
*Jonker-Pool G., Van Basten J.P., Hoekstra H.J., Van Driel M.F., Sleijfer D.T., Mensink H.J.A., Schraffordt Koops H., Van de Wiel H.B.M. (The Netherlands)*
- 020** Erectile dysfunction following Nd: YAG visual laser assisted prostatectomy (VLAP)  
*Chen J., Laufer M., Kaver I., Braf Z. (Israel)*

## THURSDAY, SEPTEMBER 14, 1995

16:00-17:30 Round Table II: Animal Models for Impotence Research

**Moderator:** I. Saenz de Tejada (Spain)


- Speakers:**
- R5** Chronic in vivo model monitoring penile erection  
*F. Giuliano (France)*
  - R6** Erection induced by pelvic and dorsal nerve stimulation  
*E. Pescatori (Italy)*
  - R7** Model for ischemia-reperfusion injury of the corpora cavernosa  
*I. Saenz de Tejada (Spain)*
  - R8** Study of erection in the pithed rat  
*Y. Vardi (Israel)*

# SYNOPSIS

WEDNESDAY		THURSDAY	
Time	Session	Time	Session
		08:00 09:30	Round Table I: Pharmacotherapy for Impotence
		09:30 10:00	Coffee Break
		10:00 12:30	Podium I: Section A: Clinical Pharmacology Section B: Basic Pharmacology
		12:30 14:00	Lunch
		14:00 15:30	Podium II: Physiology Pathophysiology
		15:30 16:00	Coffee Break
		16:00 17:30	Round Table II: Animal Models for Impotence Research
15:00 20:00	Registration	17:30 18:30	Informally Discussed Posters
20:00 20:35	Opening Ceremony Lecture: Eros through the Art		
21:30	Welcome Reception		

- All presentations will take place at Gina Bachauer Hall.
- Discussion Posters will be on display at Aristotle Room B and Informally Discussed Posters at Aristotle Room A.





# THE PRIME OF LIFE

BY

DAVID BAILEY

The processes of ageing have always been debilitating and inevitable. The Prime of Life, it seems, is over almost as soon as it's achieved.

Uro-Gynaecology is a new field of expertise from the pharmaceutical division of Groupe Fournier. Its portfolio includes several significant products - some new, some firmly established by our affiliate, Debat - all designed to help keep your patients in their Prime for as long as possible.

- Products for men that can stop BPH in its tracks.
- Products for women that deliver HRT more effectively and more comfortably.
- One of the world's most successful treatments for urge incontinence.
- A dramatic new development that corrects erectile dysfunction sensitively and practically.

But, embracing all these products, is our commitment to harness this unique range of uro-gynaecological expertise within a caring, sensitive approach to patients who often have difficulty and embarrassment acknowledging their problems.

The processes of ageing have always been debilitating and inevitable. Groupe Fournier are determined to help keep patients in their prime for longer.



— GROUPE —  
FOURNIER

**URO-GYNAECOLOGY**

## KEEPING THEM IN THEIR PRIME

# SYNOPSIS

FRIDAY		SATURDAY	
Time	Session	Time	Session
08:00 08:30	State-of-the-art-Lecture I: Impotence Research	08:00 08:30	State-of-the-art-Lecture II: Peyronie's Disease
08:30 10:00	Round Table III: Veno-occlusive Mechanism	08:30 10:00	Round Table V: Penile Revascularization
10:00 10:30	Coffee Break	10:00 10:30	Coffee Break
10:30 12:30	Podium III: Diagnostic and Treatment	10:30 12:30	Round Table VI: Prosthetic Surgery for Impotence
12:30 14:00	Lunch	12:30 13:30	Lunch
14:00 15:30	Round Table IV: Androgens and Erection	13:30 15:45	Poster Session II: Medical and Surgical Treatments
15:30 16:00	Coffee Break	15:45 16:00	Closing Remarks
16:00 18:15	Poster Session I: Basic, Pathophysiology and Diagnostics		
18:30 19:30	Business Meeting		
20:30	Barbecue Party		

- All presentations will take place at Gina Bachauer Hall.
- Discussion Posters will be on display at Aristotle Room B and Informally Discussed Posters at Aristotle Room A.

# THURSDAY, SEPTEMBER 14, 1995

17:30-18:30 Informally discussed posters

- P1** The microscopic anatomy of the human penis  
*Asvestis C., Kapatsi P., Gekas A. (Greece)*
- P2** Localization of vasoactive intestinal polypeptide (VIP) in penile erectile tissue of potent and impotent men  
*Petraki C., Constantinides C., Petraki K., Constantinides E., Moybayd F. (Greece)*
- P3** Collagen characterization in the corpus cavernosum of men with erectile dysfunction  
*Petraki C., Constantinides C., Petraki K. (Greece)*
- P4** Comparison of elastin content and contractility in human corpus cavernosum  
*Kimura K., Kawanishi Y., Numata A., Yuasa M., Tamura M., Kagawa S. (Japan)*
- P5** Phylogenetic aspects of penile blood supply  
*Droupy S., Giuliano F., Benoit G., Jardin A. (France)*
- P6** Epidemiological study of erectile dysfunction  
*Lamberts G., Claes P., Merckx L. (Belgium)*
- P7** Microvascular damage in vasculogenic impotencies  
*Curri S.B., Vaccari R., Albergati F., Lattarulo P., Menchini Fabris F., Pitus F. (Italy)*
- P8** Androgens and erection: a historical review of the role of androgens in erectile function (1830-1934).  
*Dunsmuir W.D. (United Kingdom)*
- P9** Frequency of endocrine causes of erectile dysfunction  
*Alici B., Akpınar H., Özkara H., Akkus E., Hattat H. (Turkey)*
- P10** The low testosterone as normal value in patients with erectile difficulty  
*Constantinides C., Constantinides E., Moybayd F., Petraki C., Tsihlakis M., Bourli A. (Greece)*
- P11** Venopathy incidence in surgical veno-occlusive dysfunction patients  
*Tullii R., Mancini S., Pangratis N., Guillaux G., Lorenzini L. (Italy)*
- P12** Frequency of erectile dysfunction in patients with benign prostatic hyperplasia before prostatectomy  
*Segenreich E., Israilov S., Shmueli J., Galili Y., Servadio C. (Israel)*
- P13** Erectile dysfunction following minimally invasive treatments for prostate cancer.  
*Broderick G.A., Chaikin D.C., Malkowicz S.B., Malloy T.R., Wein A.J. (U.S.A.)*
- P14** Is positive intracorporeal papaverine test always indicating normal penile vascular system  
*Kadioglu A., Erdogru T., Cayan S., Usta M., Cimen K., Tellaloglu S. (Turkey)*
- P15** Comparison of different methods to detect vascular disturbances in erectile dysfunction  
*Lenk S.V., Stockheim D., Mutze S., Wilhelm H. (Germany)*
- P16** Color doppler sonography, may it evaluate erectile dysfunction?  
*Mendonca E., Al Assal F., Raskin B., Al Assal R., Baracho A.L. (Brazil)*

## THURSDAY, SEPTEMBER 14, 1995

17:30-18:30 Informally discussed posters

- P17** Cavernosography technique, indications and results. Experience in 1131 patients  
*Al Assal F., Lerner J.S., Al Assal R., Kardosh C.B., Mendonca E., Raskin B. (Brazil)*
- P18** Penile hemodynamics in men impotent associated with failure to respond to intracavernosal therapy  
*Vlachiotis J., Christodoulou K. (Greece)*
- P19** Biochemical energy of detrusor contraction and detrusor muscle contractile power as measurable clinical test of pelvic (penile) autonomic neuropathy  
*Nale D., Micic S., Popovic S. (Yugoslavia)*
- P20** First experience with corpus cavernosum EMG in 9 normal healthy potent volunteers  
*Vrijhof H.J.E.J., Reulen F., Spaans F., Janknegt R. (The Netherlands)*
- P21** Computed-assisted evaluation of the smooth muscle electromyogram of the corpora cavernosa (CC-EMG) by Fast-Fourier-Transformation (FFT)  
*Stief C.G., Schlote N., Hauck E., Hinrichs H., Ückert S., Truss M.C., Jonas U. (Germany)*
- P22** Evoked activity recorded from the cavernous body and genital skin  
*Colacoglu Z., Ertekin C., Altay B. (Turkey)*
- P23** MR imaging in the diagnosis of fracture of the penis with urethral injury  
*Fedel M., Venz S., Kalaitzis C., Andreeben R., Loening S. (Germany)*
- P24** Efficacy of usage of medication "Caverject" for treatment of different erectile dysfunction forms  
*Scheplev P.A., Chibisov M.P., Gvozdev M. (Russia)*
- P25** Alprostadil (Prostin VR) in treatment of impotence  
*Micunovic M.D., Stavridis A. (Former Yugoslav Republic of Macedonia)*
- P26** The combination of PGE<sub>1</sub> and phentolamine for a selfinjection program for impotence treatment  
*Meinhardt W., De la Fuente R.B., Lycklama á Nijeholt A., Vermeij P., Zwartendijk J. (The Netherlands)*
- P27** Value of prostaglandin E<sub>1</sub> in the management of erectile dysfunction  
*Chitale S., Hadfield J., Waterfall N., Chaudhari. (United Kingdom)*
- P28** Our experience with PGE<sub>1</sub>  
*Kovalyov V.A., Korolyova S.V., Martov A.G. (Russia)*
- P29** Long-term results of intracavernous self injection of vasoactive drugs  
*Rodriguez-Vela L., Gonzalvo A., Berne M., Carela J., Gil P., Paúl F.J., Rioja L.A. (Spain)*
- P30** Pain and fibrosis following ICI therapy: personal experience on pathogenetic mechanisms  
*Austoni E., Mantovani F., Colombo F., Fenice O. (Italy)*
- P31** The percentage of fibrosis in long term therapy with intracavernosal injections of vasoactive agents  
*Constantinides C., Petraki C., Moybayd F., Constantinides E., Bourli A. (Greece)*

## THURSDAY, SEPTEMBER 14, 1995

17:30-18:30 Informally discussed posters

- P32** Self injection therapy and counselling- How good can they get?  
*Lundquist B. (Sweden)*
- P33** Etilefrine in the prevention of prolonged erection after diagnostic pharmacological stimulation  
*Cormio L., Nisén H., Ruutu M., Selvaggi F.P. (Italy-Finland)*
- P34** Trazodon versus placebo for impotence treatment, a double-blind multicentre trial  
*De da Fuente R.B., Kropman R.F., Meinhardt W., Lycklama á Nijeholt A.A.B., Zwartendijk J. (The Netherlands)*
- P35** Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology  
*Vrijhof H.J.E.J., Delaere K.P.J. (The Netherlands)*
- P36** Radical surgery of penile primary carcinoma with preservation of sexual function  
*Austoni E., Mantovani F., Colompo F., Fenice O. (Italy)*
- P37** The radical cystoprostatectomy with preservation of sexual function  
*Khvadagiani G., Pertia A., Chogogidze T., Managadge L. (Republic of Georgia)*
- P38** Compined coronal-scrotal access for penile surgery: 15 years experience on 720 patients  
*Austoni E., Mantovani F., Colompo F., Fenice O. (Italy)*
- P39** Electromagnetic field in treatment of sexual function disorders  
*Borzhievsky A., Sokolov S., Shulyak A., Colubev Y. (Ukraine)*
- P40** Flaccidity of the tunica albuginea. It's a cause of veno-occlusive dysfunction?  
*Al Assal F., Degni M., Al Assal R., Camargo O. (Brasil)*
- P41** Radical reduction of venous outflow for correction of venous impotence  
*Perovic S., Milosevic A., Dordevic M. (Yugoslavia)*
- P42** Male sexual venous dysfunction  
*Diaz A., Diaz K., Montenegro R. (Ecuador)*
- P43** Late results of venous leakage surgery  
*Vlachiotis J., Christodoulou K. (Greece)*
- P44** Veno-occlusive dysfunction. Surgical therapy and late results  
*Al Assal F., Raskin B., Al Assal R., Baracho A., Garrido V. (Brasil)*
- P45** A new technique for operative treatment of venous erectile impotence  
*Kogan M.I., Seleznev G.G., Sizyakin D.V., Geneidi G. (Russia)*
- P46** The arbitrary contraction of autotransplanted muscle as an analogue to physiological erection  
*Sheplev P.A., Adamyan R.T., Abbacumov L.A., Amosov F.R. (Russia)*
- P47** Arterialization of DDV: A pilot protocol in order to minimize the high rate of postoperative failures  
*Constantinides C., Constantinides E., Moybayd F., Petraki C., Petraki K., Bourli A. (Greece)*
- P48** Method of penile revascularization. 7 years experience  
*Kovalyov V., Korolyova S. (Russia)*
- P49** Penis revascularization: Results in 56 patients  
*Kovalyov V., Korolyova S. (Russia)*

- P50** Contemporaneous penile implantation of two different types of prosthesis  
*Vaccari R., Lattarulo P., Albergati F. (Italy)*
- P51** Aneurismatic dilatation of inflatable penile prosthesis: the problem is still unsolved  
*De Luca V., Zanotelli T., Taher B., Frego E., Giambromi L., Da Pozzo G.P., Pezzotti G., Cancarini G., Cosciani Cunico S. (Italy)*
- P52** Systemic absorption of intracavernous gentamicin in penile prosthesis operations  
*Ulker V., Semerci B., Kosay S., Önal A. (Turkey)*
- P53** Priapism: results of operative treatment with cavernoglandular shunt (Al-Ghorab procedure)  
*Chkhotua A.B., Ujmajuridze N.S., Managadze L.G. (Republic of Georgia)*
- P54** Cavernosum-spongiosum shunts. Diagnostic and surgical therapy  
*Al Assal R., Raskin B., Al Assal F., Degni M., Camargo O. (Brazil)*
- P55** Etiology and treatment of premature ejaculation  
*Diaz A., Eiguez F. (Ecuador)*
- P56** Ultrasonographic evaluation of Peyronie's disease  
*Pistevou-Gompaki K., Yannakoyorgos K., Destouni E. (Greece)*
- P57** Cavernosography: its place in the surgical strategy of La Peyronie disease  
*Lansiaux P., Cornud F. (France)*
- P58** Our attitude in the management of the penile curvature, with special focusing in the functional state after graft placement  
*Martin Morales A., Gutierrez Calzada J.L., Burgos Rodriguez R. (Spain)*
- P59** Management of Peyronie's disease with cavernosoplasty  
*Chkhotua A.B., Ujmajuridze N.S., Managadze L.G. (Republic of Georgia)*
- P60** Penile fibrosis and Peyronie's disease. A new alternative for clinical treatment  
*Tullii R., Mancini S., Guillaux C., Pangratis N., Lorenzini L. (Italy)*
- P61** Peyronie's disease. Our experience  
*Rodriguez-Vela L., Berné J.M., Carela J., Gonzalvo A., Gil P., Paúl F.J., Rioja L.A. (Spain)*
- P62** Incision venous patch in Peyronie's disease  
*Akkus E., Özkara H., Alici B., Hattat H. (Turkey)*
- P63** Initial experience with incision venous patch procedure (Lue technique) in Peyronie's disease  
*Kadioglu A., Erdogru I., Usta M., Cimen K., Tellaloglu S. (Turkey)*
- P64** Treatment of Peyronie's disease with colchicine  
*Reithmeier W., Neumann H.G., Pust R.A., Sparwasser C. (Germany)*
- P65** Treatment of Peyronie's disease by radiotherapy  
*Pistevou-Gompaki K., Yannakoyorgos K., Destouni E. (Greece)*
- P66** Psychotherapy for sexual dysfunction in couples  
*Kameya Y. (Japan)*
- P67** Comparative investigations in organically and psychogenically impotent patients  
*Djordjevic B., Stojkovic D., Topuzovic C., Markovic P. (Yugoslavia)*

- P68** Psychiatric aspects on 295 males with sexual disorders  
Basile Fasolo C., Santinami A., Castrogiovanni P. (Italy)
- P69** Sexual behaviour and partner relationship after radical pelvic surgery  
Lenk S.V., Pufahl B., Schnorr D., Loening S.A. (Germany)
- P70** The role of stress in sexual dysfunction in relation to the socioeconomical status and the age of Greek men population  
Constantinides C., Constantinides E., Moybayd F., Bourli A. (Greece)
- P71** Psychogenic erectile dysfunction: A new integrated psychopharmatherapeutic approach  
Jallous H., Coglitore M.T., Marandola P., Marandola C. (Italy)
- P72** Sequential male orgasm  
Vargas M.C.G.B., Sá C. (Brazil)
- P73** Visual erotic and vibrotactile stimulation and intracavernous injection in differential diagnosis of male erectile dysfunction  
Incrocci L., Hop W.C.J., Schröder F.H., Slob A.K. (The Netherlands)
- P74** Long-term follow-up of hydraulic penile prostheses - 506 cases  
Oberbeck D., Schreiter F. (Germany)



# FRIDAY, SEPTEMBER 15, 1995

## 08:00-08:30 State-of-the-art Lecture I:

- S1** Impotence Research: Where do we stand?  
*R.J. Krane (U.S.A.)*

## 08:30-10:00 Round Table III: Venno-occlusive mechanism: Innovations and Controversies

**Moderator:** **J. Ebbelhøj (Denmark)**

- Speakers:**
- R9** The concept of abnormal drainage of the corpora cavernosa  
*J. Ebbelhøj (Denmark)*
- R10** Venno-occlusive mechanism: anatomical and physiological considerations  
*P. Bondil (France)*
- R11** Hemodynamics of the erect penis  
*D. Hatzichristou (Greece)*
- R12** Biomechanics of erection  
*I. Goldstein (U.S.A.)*
- R13** Venno-occlusive dysfunction: a morphological approach  
*E. Wespes (Belgium)*

## FRIDAY, SEPTEMBER 15, 1995

10:30-12:30 Podium III: Diagnostic and Treatment

**Moderators: E. Meuleman (The Netherlands) - I. Moncada (Spain)**

- 021** Provocability in corpus-cavernosum EMG compared to other neurophysiological and vascular parameters in 72 diabetics with erectile dysfunction  
*Fabra M., Johans A., Porst H., Scheider E. (Germany)*
- 022** Maximal cavernous smooth muscle relaxation induced with PGE<sub>1</sub> vs booster trimix and visual sex stimulation  
*Nisen H., Ruutu M. (Finland)*
- 023** Color-coded duplex sonography as a means to determine the presence and possible therapeutic implications of connections between dorsal and cavernous arteries in impotent men  
*Knispel H.H., Wegner H.E.H., Andersen R., Banzer D., Miller K. (Germany)*
- 024** Role of the penile venous system in regulation of erection  
*Kogan M.I., Uryvayev Y.M. (Russia)*
- 025** Long-term follow-up of penile vein ligation in 100 patients  
*Kromann-Andersen B., Hansen F., Gerstenberg T., Metz P. (Denmark)*
- 026** Erectile function after traumatic rupture of penile tunica albuginea  
*Pourmand G., Mehraei A., Nikoubakht M., Afshar K. (Iran)*
- 027** Is the section of the suspensory ligament of penis really efficient for penile lengthening? : Preliminary results of an anatomical study  
*Bondil P., Delmas V. (France)*
- 028** Penis lengthening  
*Roos H., Constantinides C., Lissoos I. (South Africa - Greece)*
- 029** ESS - Erectile Supporting System, a Low Pressure Penile Prosthesis  
*Pedersen J., Hedelin H., Nilsson S., Olsson A.M. (Sweden)*
- 030** Magnetic resonance imaging in malfunctioning inflatable penile prosthesis  
*Moncada I., Jara J., Lledó E., Chamorro F.G., Durán R., Escribano G., Hernández C. (Spain)*

## FRIDAY, SEPTEMBER 15, 1995

14:00-15:30 Round Table IV: Androgens and Erection

**Moderator:** K.-E. Andersson (Sweden)

- Speakers:**
- R14** Central action of androgens  
*K.-E. Andersson (Sweden)*
  - R15** Action of androgens on the erectile tissue  
*O. Rampin (France)*
  - R16** Androgens and aging: Is there a male climacteric?  
*A. Vermeulen (Belgium)*
  - R17** Hormonal screening and treatment  
*J. Buwat (France)*

# FRIDAY, SEPTEMBER 15, 1995

16:00-18:15 Poster Session I: Basic, Pathophysiology and Diagnostic

Moderators: Y. Vardi (Israel) - R. Pickard (United Kingdom)

- D1** Characteristics of the specificity of vasoconstrictor and vasodilator systems in diminishing erectile function in vivo  
*Gofton W.T., Heaton J.P.W., Ge S.P., Morales A., Adams M.A. (Canada)*
- D2** Combined assessment of inflow resistance properties and tumescence in the isolated perfused rat penis  
*Adams M.A., Ge S.P., Morales A., Heaton J.P.W. (Canada)*
- D3** Stimulation of the dorsal nerve of the penis increases c-fos expression in spinal neurons in the rat  
*Rampin O., Gougis S., Giuliano F., Rousseau J.P. (France)*
- D4** Erectile dysfunction in diabetic rats  
*Vardi Y., Ari G., Finberg J.P.M. (Israel)*
- D5** Alpha adrenergic receptor subtypes in rat corpus cavernosum by in situ hybridization: preliminary results  
*Veronneau-Longueville F., Giuliano F., Rampin O., Jardin A. (France)*
- D6** Biochemical evaluation of nitrenergic innervation of the rat penis  
*Bernabé J., Meulemans A., Rampin O., Giuliano F. (France)*
- D7** Alterations in <sup>125</sup>I endothelin and <sup>3</sup>H-NOARG binding on diabetic rat cavernosa  
*Sullivan M.E., Bell C.R.W., Dashwood M.R., Thompson C.S., Mikhailidis D.P., Morgan R.J. (United Kingdom)*
- D8** Comparison of the distribution and function of nitric oxide containing nerves in corpus cavernosum and spongiosum of the dog  
*Hedlund P., Larsson B., Alm P., Andersson K.E. (Sweden)*
- D9** Comparative neurophysiology: Human corpus cavernosum, human clitoris and rabbit corpus cavernosum  
*Broderick G.A., Hypolite J.A., Levin R.M., Canning D.A., Duckett J. (U.S.A.)*
- D10** Penile arteries in human: origin and variations  
*Droupy S., Benoit G., Giuliano F., Blanchet P., Jardin A. (France)*
- D11** Basic pharmacokinetics of intracavernous injections  
*De Mayer J.M., Oosterlinck W. (Belgium)*
- D12** Pharmacokinetic study of intracavernosal VIP  
*Oakes R.A., Coppard N.J. (U.K.)*
- D13** Prevalence of polyneuropathy in impotence  
*Vardi Y., Yarnitzky D., Nassar S., Livne P.M. (Israel)*
- D14** Ultrasound angiography - a new diagnostic tool for evaluation of impotent patients  
*Klingler H.C., Kratzik C. (Austria)*
- D15** The effect of intracorporeal injection + genital and audio-visual sexual stimulation vs second injection on penile color doppler sonography parameters  
*Montorsi F., Guazzoni G., Barbieri L., Rigatti P., Pizzini G., Miani A. (Italy)*
- D16** Alterations in penile hemodynamics in men impotent following nerve sparing radical cystoprostatectomy  
*Vlachiotis J., Christodoulou K. (Greece)*

## FRIDAY, SEPTEMBER 15, 1995

### 16:00-18:15 Poster Session I: Basic, Pathophysiology and Diagnostics

- D17** The significance of histopathological changes of normal tunica albuginea in Peyronie's disease  
*Aydos K., Baltaci S., Beduk Y., Uluoglu O., Anafarta K. (Turkey)*
- D18** Peyronie's disease: Functional and anatomic testing with color duplex doppler ultrasound  
*Broderick G.A., Rouner E., Arger P. (U.S.A.)*
- D19** Correlation of nocturnal penile tumescence monitoring, duplex ultrasonography and infusion cavernosometry on the diagnosis of erectile dysfunction  
*Sattar A.A., Wery D., Golzarian J., Raviv G., Schulman C.C., Wespes E. (Belgium)*
- D20** A new harmless method for measuring accurately the axial penis rigidity  
*Roselló-Barbará M. (Spain)*
- D21** The axial extensibility of the flaccid penis: comparative study between a group with la Peyronie's disease (63 cases) and a control group (586 cases)  
*Bondil P., Salti A., Sabbagh R., Masmoudi S. (France)*
- D22** Is the erect penile length < 7cm, a reliable guideline for penile lengthening?  
*Bondil P., Salti A., Sabbagh R., Costa P., Navratil H., Daurés J.P. (France)*

### 18:30 - 19:30 Business Meeting

### 20:30 - 24:00 Barbecue Party

# SATURDAY, SEPTEMBER 16, 1995

## 08:00-08:30 State-of-the-art Lecture II:

- S2** Peyronie's disease: Reconsidering an old disease  
*J. Pryor (United Kingdom)*

## 08:30-10:00 Round Table V: Penile revascularization: 20 years experience

**Moderator:** **V. Michal (Czech Republic)**

- Speakers:**
- R18** Historical perspectives  
*V. Michal (Czech Republic)*
- R19** Diagnostic approach and selection criteria  
*E. Meuleman (The Netherlands)*
- R20** Indications, techniques and results  
*K.P. Jünemann (Germany)*
- R21** Objective assessment and future perspectives  
*M. Sohn (Germany)*

# SATURDAY, SEPTEMBER 16, 1995

10:30-12:00 Round Table VI: Prosthetic surgery for impotence

**Moderator:** E. Austoni (Italy)

- Speakers:**
- R22** Indications and device selection criteria  
*C. Gingell (United Kingdom)*
  - R23** Surgical considerations  
*E. Austoni (Italy)*
  - R24** Multicenter clinical studies: Results and patient satisfaction  
*R. Lewis (U.S.A.)*
  - R25** Complications: implications and management  
*A. Allona-Almagro (Spain)*

*Supported through an educational grant from MENTOR UROLOGY, Inc.*

# SATURDAY, SEPTEMBER 16, 1995

13:30-15:45 Poster Session II: Medical and Surgical Treatments

Moderators: E. Wespes (Belgium) - T. Gerstenberg (Denmark)

- D23** Intracavernous self-injection program: analysis of long-term results with prostaglandin E<sub>1</sub> (Alprostadil)  
*Cuzin B., Meunier P., Darjinoff J.J., Galaup J.P., Dubernard J.M. (France)*
- D24** Comparative evaluation of 4 protocols of intracorporeal injection for treatment of 348 patients with erectile dysfunction  
*Segenreich E., Israilov S., Shmueli J., Servadio C. (Israel)*
- D25** Oral prostacyclin as an enhancer of the erectile response produced by intracavernous injection of prostaglandin E<sub>1</sub>.  
*Kawanishi Y., Kimura K., Tanimoto S., Yamanaka M., Matsushita K., Yamamoto A., Numata A., Yuasa M., Tamura M., Kagawa S. (Japan)*
- D26** Value of nitric oxide donor linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction  
*Knispel H.H., Wegner H.E.H., Miller K. (Germany)*
- D27** Long-term intracavernous pharmacotherapy improves penile hemodynamics but does not cure impotence in patients with vasculogenic erectile dysfunction  
*Montorsi F., Guazzoni G., Barbieri L., Rigatti P., Pizzini G., Miani A. (Italy)*
- D28** A novel auto-injector for the administration of vasopotin, a new treatment for erectile dysfunction  
*Gerstenberg T. (Denmark)*
- D29** Intracavernous pharmacotherapy and sexual counselling for psychogenic impotence: criteria for patient selection and analysis of long-term results  
*Montorsi F., Graziottin A., Guazzoni G., Barbieri L., Rigatti P., Pizzini G., Miani A. (Italy)*
- D30** A comparative study with intracavernosal injection of prostaglandin E<sub>1</sub>(PGE<sub>1</sub>) versus vacuum constriction devices (VCD) in the treatment of erectile dysfunction  
*Fedel M., Andereeben R., Sudhoff F., Kalaitzis C., Loening S. (Germany)*
- D31** Aorto-femoral surgery and sexual function. A prospective study  
*Cormio L., Edgren J., Lepantalo M., Lindfors O., Nisén H., Saarinen O., Ruutu M. (Italy)*
- D32** Individualized approach for penile revascularization - Clinical experience in 30 patients  
*Vardi Y., Har-Shai Y., Ofer Y., Engel A., Livne M.P. (Israel)*
- D33** The long-term follow-up of both deep dorsal penile vein resection only or combined with detachable balloons and coils for erectile dysfunction due to venous leakage  
*Pit M.J., Lycklama à Nijeholt A.A.B., Kropman R.F., Zwartendijk J. (The Netherlands)*



## SATURDAY, SEPTEMBER 16, 1995

### 13:30-15:45 Poster Session II: Medical and Surgical Treatments

- D34** Two years of experience with verapamil in Peyronie's disease in two different centers  
*Nicolai M., Arena F., De Thomas R., Peracchia G., Cipollone G., Cortellini P., Tenaglia R. (Italy)*
- D35** Peyronie's disease: Treatment with local interferon-a2b  
*Wegner H.E.H., Knispel H.H., Andersen R., Miller K. (Germany)*
- D36** The Ebbelhøj-Metz's introflexed plication of the tunica albuginea: our experience about more than 5 years  
*De Luca V., Pezzotti G., Taher B., Tralce L., Cancarini G., Giambroni L., Botturi A., Cosciani Cunico S. (Italy)*
- D37** Plaque incision and venous grafting for severe Peyronie's disease: long-term clinical and hemodynamic results  
*Montorsi F., Guazzoni G., Da Pozzo L., Rigatti P., Pizzini G., Miani A. (Italy)*
- D38** Neophallic construction with rectal abdominal muscle. Clitoral transposition and histeroannessiectomy in single stage  
*Austoni E., Mantovani F., Colombo F., Fenice O. (Italy)*
- D39** Functional electromyostimulation of corpus cavernosum penis (FEMCC) - A new therapy for erectile dysfunction  
*Stief C.G., Weller E., Meschi M., Truss M.C., Ückert S., Jonas U. (Germany)*
- D40** Use of virtual reality in the treatment of impotence, premature ejaculation, orgasmic disorders and lack of sexual desire: a preliminary report  
*Optale G., Munari A., Rizzo C., Nasta A., Pianon C., Viggiano G., Verde J.B. (Italy)*
- D41** Clomipramine and sexual functioning in sexually dysfunctional and functional men  
*Haensel S.M., Rowland D.L., Kallan K.T.H., Slob A.K. (The Netherlands)*
- D42** Premature ejaculation - Electrophysiological study technique review and classification  
*Tullii R., Ferreira R., Mancini S., Guillaux C., Pangratis N. (Italy)*
- D43** Fluoxetine and sexual counselling for premature ejaculation  
*Graziottin A., Montorsi F., Guazzoni G., Rigatti P., Pizzini G., Miani A. (Italy)*
- D44** Evaluation of neurotomy in primary premature ejaculation patients  
*Tullii R., Mancini S., Ferreira R., Guillaux C., Pangratis N. (Italy)*

# SCIENTIFIC INFORMATION

## GUIDELINES FOR PRESENTERS

All presentations will take place at **GINA BACHAUER HALL**. All posters will be on display during the whole duration of the meeting at **ARISTOTLE Room A and Room B**. There will be no parallel activities to give the opportunity to all participants to attend all sessions.

## INSTRUCTIONS FOR PODIUM PRESENTATION

Presentations should not exceed 7 min. and will be followed by 5 min. discussion time. The total time allotted for each presentation is 12 minutes. Double projection of 5×5 cm slides and a laser pointer will be available. Slides should be given at the slide editing room one hour before the session start time. Please note that speakers must personally edit their own slides.

## INSTRUCTIONS FOR POSTER PRESENTATION

Poster size	Each poster board is 95cm width × 150cm height
Poster construction	Posters should be produced in a similar manner:
	1) Title and authors
	2) Abstract
	3) Introduction
	4) Methods
	5) Results
	6) Conclusions

Please note that letters, graphs and illustrations must be large enough to be clearly viewed from a distance of 1.5 meters. Do not glue the poster to the poster board. Push pins and double sided tape (5×5cm) will be supplied by the organizer.

### A. DISCUSSION POSTERS

Poster presentation should not exceed 3 min. and will be followed by 3 min. discussion time. The total time allotted for each presentation is 6 minutes. Double projection of 5×5 cm slides and a laser pointer will be available. Slides should be given at the slide editing room, one hour before the session start time. Posters should be on display from Thursday morning at 10:00 a.m. till Saturday afternoon at 16:00 p.m. At least one of the co-authors is expected to remain at attendance of the poster during coffee breaks to answer any points of interest raised by the viewers.

### B. INFORMALLY DISCUSSED POSTERS

Posters should be on display from Thursday morning 10:00 a.m. and should be removed on Saturday at 16:00 p.m. At least one of the co-authors is expected to be at attendance of his poster on Thursday, September 14, 1995, from 17:30 to 18:30 p.m.

# AWARD

## **Fournier - Debat Prize in Erectile Dysfunction**

Awarded for the best innovative Clinical Presentation on erectile dysfunction. The price will comprise of a 5,000 FFR reward and will be offered in each subsequent bi-annual meeting of ESIR.

### **Fournier Award Committee**

1. Dr. K.-E. Andersson (Chairman)
2. Dr. J. Buvat
3. Dr. E. Meuleman
4. Dr. F. Mortorsi
5. Dr. G. Wagner

# REGISTRATION AND ACCOMMODATION

## COMMUNICATION ADDRESSES

### Meeting Secretariat

Frei Travel Congress S.A.  
24, Nikis str.  
10557 Athens  
Greece  
Tel.: +30 1 32 20 489  
Fax: +30 1 32 19 296

### Registration Desk - Secretariat during the Meeting

Secretariat ESIR '95  
Porto Carras  
Village Inn  
Sithonia, Chalkidiki, Greece  
Tel.: +30 375 72500-4  
Fax: +30 375 71229

## REGISTRATION AND HOTEL ACCOMMODATION

### Registration fees

#### Pre-Registration (before June 12, 1995 postmarked)

ESIR members	ECU 200	Non-members	ECU 300
Accompanying persons	ECU 100	Exhibitors	ECU 100

#### Late Registration (after June 12, 1995 postmarked)

ESIR members	ECU 300	Non-members	ECU 400
Accompanying persons	ECU 130	Exhibitors	ECU 130

Registration fees for participants include: attendance of the scientific and social program, meeting material, coffees, welcome reception and barbecue party.

Registration fees for accompanying persons and exhibitors include: attendance of the social program, welcome reception and barbecue party.

## HOTEL ACCOMMODATION

Hotels Meliton and Sithonia (Porto Carras complex).

Single room      28.000 GRD / day                      Double room      32.000 GRD / day

The above room rates include breakfast and lunch.

## HOTEL ADDRESSES

### MELITON / SITHONIA BEACH HOTEL

Porto Carras  
630 81 Sithonia  
Chalkidiki-Greece

TEL: +30 375 71381/ 71221  
FAX: +30 375 71501/ 72130

## PAYMENT

All fees should be paid either by cash or credit card (VISA and MASTERCARD are only accepted) at the registration desk.

## GENERAL INFORMATION

### Venue

Porto Carras is a holiday resort set in one of the most unspoiled and picturesque regions of Greece. Porto Carras beaches have been awarded the European blue flags for the clean waters and care for the environment. The estate is surrounded by rolling hills, covered with the lush greenery of a million vines and is planted with colorful groves of almond and citrus trees. The complex boasts three hotels, a comprehensive village shopping center and a sophisticated nightlife catering for all tastes. Casino Magic's state of art american Casino and a night club are both located at Sithonia hotel.

The Congress Center is located at Village Inn, across the MARINA. The scientific program of the meeting will be hosted at Gina Bachauer Hall which is within walking distance from both hotels, Meliton and Sithonia.

Absorbing the atmosphere of traditional Chalkidiki, sample the superb Château Carras wines at the CAVA, close to the MARINA. 18 hole Golf field, water sports, riding, diving and tennis centers as well as mountain bikes are some of the sport facilities of the complex.

### Airport reception - Hotel transportation

Porto Carras is located 120 kms from Thessaloniki and its airport (Makedonia airport). Bus transportation will be available from and to the airport on September 13 and 17, 1995, for those who have made reservation before July 31, 1995.

### Transportation

Transport is relative inexpensive in Greece and very easy to find, just by asking at the reception desk of your hotel. This includes buses, taxis etc. There is also a hotel car rental service. There is a regular service every half an hour by bus and by caique (small boats), from Porto Carras to Neos Marmaras and with the fast boat "Sithonia Express" to Kallithea (every three hours) and Pefkohori (every two hours), the two main villages of the first peninsula, Kassandra. For the exact time and place of departures and arrivals please contact the reception desk. Regular routes with a fun bus are also available to the coves.

### Language

The official language of the meeting will be English. No translation will be available.

### Entrance to ESIR 95

Meeting badge is required for entrance to all scientific sessions and social events of the meeting.

## GENERAL INFORMATION

### Exhibition

An international exhibition of technical equipment and pharmaceutical products is organized at Socrates Room as well as outside of Gina Bachauer Hall.

### Confirmation of attendance

Confirmation of attendance of the meeting for all participants will be available at the registration desk on Saturday morning.

### Social events

#### EROS AND ART

##### -Painting Exhibition

A painting exhibition is organized by the art gallery Terracotta (Thessaloniki) at the congress area. Twelve Greek painters have been invited to exhibit their work on erotic themes.

##### -Invited Lecture

Eros through the art.

Speaker: Prof. Athena Schina,  
Critic and Art Historian,  
Department of Art and Archaeology,  
Athens University.

#### WELCOME RECEPTION

All participants and accompanying persons are invited to the welcome reception, which will take place at the area around the pool at Sithonia Hotel on Wednesday, September 13, 1995, at 21:30 p.m.

#### BARBECUE PARTY

Come to celebrate the foundation of ESIR on Friday, September 15, 1995, at 9:00 p.m. Enjoy some of the most delicious Greek specialties and dance till midnight.

# USEFUL INFORMATION ON GREECE

## GEOGRAPHY - HISTORY

Greece is a Mediterranean country with a total land area of 132.000 square km and more than 3.000 islands, 200 of them inhabited.

Macedonia, the Northern part of Greece, pertains to the Greek history and culture for more than 4000 years. Around the middle of the 4th century BC, Macedonia became the leading power of the Greek World thanks to King Philip II, who went from a prototype organization of his Kingdom to the pan-Hellenic Congress of 338 BC, which proclaimed the freedom and autonomy of every city, forbade war between Greeks. His last dream, the conquest of the East was destined to come true by his son, Alexander the Great: Macedonia conquered an enormous empire stretching to the ends of the known world. Its world-wide implications are due to the fact that Alexander's dream was the fusion of the West and East, through the spreading of the Greek civilization, retaining its essential values, first and foremost among them the blossoming of the individual. The excavations of the last 20 years have offered major contribution to the civilization of classical antiquity. In Pella, Vergina, Dion and other sites, archaeologists have uncovered some astonishing works of art that has filled the archaeological museum of Thessaloniki.

Chalkidiki is located in central Macedonia and is made up by three peninsulas, Kassandra, Sithonia - where Porto Carras is located- and Athos, the Holy Mountain of Orthodoxy. It was in 885 A.C. when the Byzantine Emperor Basil I officially recognized Athos as a territory belonging exclusively to monks and hermits. It laid down that only men of religion should live in the "garden of the Virgin". Since then Mouth Athos is the sole monastic state in the world, with a continuous and unbroken history. It represents the only part of Greece where for more than a thousand years the Greek-Christian heritage, Greek letters and the true Byzantine style of workshop have been preserved. The twenty monasteries are richly stocked with artistic treasures of the Christian Orthodox past.

Land and sea, tranquillity and eternity, forests of beeches, beguiling coves and picturesque villages compose a unique land to explore.

## PEOPLE AND LANGUAGE

The population of Greece is about 10 million. Greek is the official language, but English is widely spoken.

## CLIMATE AND DRESS

The climate is warm but equable (range from 24°C to 31°C, i.e. 75°F to 87°F). September is a sunny month and the sea is ideal for swimming. Light summer clothing should be worn. Dress is generally informal.

# USEFUL INFORMATION ON GREECE

## FOOD

Greece is famous for its national cuisine and for very special tastes. It is regarded by many as the paradise for fresh fish, vegetables and plenty of fruits, local wine, home made cheese and bread.

## DRINKING WATER

Greece is known for its safe and clean drinking water. Tap water is safe for drinking.

## ELECTRICITY

The local voltage is 220V.

## SHOPPING

Greece is famous for its jewellery, clothes, leather goods etc., exported internationally. Several shops are located at Porto Carras and Neos Marmaras.

## SIGHTS IN CHALKIDIKI

MOUNT ATHOS Enjoy the mystic atmosphere of the Byzantine era in this unique physical and spiritual paradise, meeting intellectual people from all over the world.

PETRALONA One of the most important caves with interesting paleological finds.

STAGIRA Aristotle's birthplace.

OLINTHOS Ruins of the homonymous colony of the Athenians.

TORONI Ruins of the old fortifications, from antiquity up to the byzantine era.

## CURRENCY

The official currency in Greece is Greek Drachma (GRD). One US dollar is approximately equivalent to 222 GRD and one ECU is approximately 295 GRD.

## BANKS

The Bank of Crete in Sithonia Hotel and the National Bank of Greece in Neos Marmaras (nearby village in Porto Carras) are open weekdays 09:00-13:30.

## CREDIT CARDS

Credit and charge cards are acceptable at most of Porto Carras facilities. For any problem contact the relevant credit card company involved or the reception desk.

## SMOKING

Smoking is not allowed in public transport, government offices and public places. In Porto Carras smoking is not allowed within the Gina Bachauer Hall where the meeting will take place.



## OPTIONAL TOURS

### 14-09-1995: Thessaloniki city tour\*:

09:00 Departure from the hotel for the city tour, where you can visit the Archaeological Museum of Thessaloniki, a true surprise to the visitor, mainly because of the stunning and unique finds of Vergina and Sindos. The golden exhibits of King Philip II era, can be seen and also other objects of Alexander the Great period from his birthplace, Macedonia. The Byzantine monuments of the city where the greatness produce deep impression and awe. Continue with the highlights of Thessaloniki.

15:00 Return to hotel.

*Price per person:* GRD 12,000

### 15-09-1995: Pella-Vergina\*:

08:30 Guided tour to Vergina the old capital, where you can see the cemetery of Iron Age and of the Geometric Era and the archaeological sites with unique quality. Proceed to Pella, the second capital of Macedonia at the lights of its power as well as Vergina the birthplace of Alexander the Great. In 1957, an accidental find enabled the archaeologists to locate the exact site of the well laid out city with its impressively broad streets and large mansions decorated with mosaics of real beauty. You will also visit the local archaeological Museum.

Duration: 8 hours approx.

*Price per person:* GRD 16,000

### 16-09-1995: Dion\*:

08:30 Guided tour to Dion, where the archaeological finds reveal the presence of an extensive and fully organized site of the Macedonians comparable to the major sanctuaries of Southern Greece, cult to the Gods of Olympus.

Duration: 7 hours.

*Price per person:* GRD 15,000

### 17-09-1995: Excursion-Cruise to Mount Athos\*\*:

08:00 Departure from Porto Carras by coach, to the port of Ouranoupolis. From Ouranoupolis you will sail, at the distance of 500 meters, the West coast of Mount Athos. You will see breathtaking monasteries, in this monastic state, the bastion of Orthodoxy for over a thousand years where tradition and spirituality have survived.

Duration of tour and cruise: 6 hours.

*Price per person:* GRD 13,000

\* Minimum participants: 20 persons

\*\* Minimum participants: 40 persons

Note: All the above prices do not include any meals or drinks during breaks.

## PRE-AND-POST- CONGRESS EXCURSIONS

### Tour A' : Rhodes island:

Rhodes island, meet all pre-conditions in terms of geography, climate, availability of quality services, safety, cultural and historical interest, natural beauty and languages spoken locally. An ideal place to enjoy sun, sea and the Greek hospitality.

Reach from Thessaloniki: By air. Price per person round trip: GRD 38,000.

Availability in category A' category hotels. Price per room per day on bed and breakfast basis.

Single: GRD 26,000.

Double: GRD 36,000.

### Tour B' : Skiathos island:

Lies on the West side of Aegean, the island is covered with greenery and offers visitors beautiful sandy beaches and vivid night life. Reach from Thessaloniki, by hydrofoil. Price per person round trip: GRD 20,400.

Availability in category A' category hotels. Price per room per day on bed and breakfast basis.

Single: GRD 28,000.

Double: GRD 39,000.

### Tour C' : Santorini island:

The famous island of Santorini, where the myth says that the sunken city of Atlantis used to be. The sunset is one of the most famous and picturesque in the world on the breathtaking view from the Caldera. Perfect choice for those who are seeking a different life-style.

Reach from Athens: By air. Price per person round trip: GRD 29,200.

Availability in category A' category hotels. Price per room per day on bed and breakfast basis.

Single: GRD 26,000.

Double: GRD 32,000.

### Notes:

- Air and hydrofoil fares are subject to change without notice.
- Confirmation for accommodation no later than June 12th, 1995.
- 20% of total amount must be send up to July 31st, 1995.  
Full payment by August 15th, 1995.

For more information and accommodation, please contact FREI S.A.

# ACKNOWLEDGMENTS

The organizing committee would like to thank the main sponsors and the meeting, for their major support to the idea of the European Society for Impotence Research and their generous funding to ESIR '95.

We would like also to thank "DOMOTECHNIKI" S.A.' and "CASINO MAGIC PORTO CARRAS S.A.". Their contribution made "EROS AND ART " feasible.

## SUPPORTED BY

- ARISTOTLE UNIVERSITY OF THESSALONIKI
- MINISTRY OF MACEDONIA AND THRACE

## MAIN SPONSORS

- MENTOR UROLOGY
- SCHWARZ PHARMA
- THE UPJOHN COMPANY

## SPONSORS

- FOURNIER

## EXHIBITORS

- AMERICAN MEDICAL SYSTEMS
- DACOMED - ELECTRATHA
- CARFAX PUBLISHING COMPANY
- MENTOR UROLOGY
- MISSION PHARMACAL COMPANY
- OSBON INTERNATIONAL
- SCHWARZ PHARMA
- STOCKTON MACMILLAN
- THE UPJOHN COMPANY

## AUTHORS INDEX

<b>Abbacumov L.A.</b>	P46	<b>Buvat J.</b>	R17
<b>Adams M.A.</b>	D1, D2	<b>Calas A.</b>	O16
<b>Adamyan R.T.</b>	P46	<b>Camargo O.</b>	P40, P54
<b>Afshar K.</b>	P9, P62	<b>Cancarini G.</b>	D36, P51
<b>Akpinar H.</b>	P9	<b>Canning D.A.</b>	D9
<b>Al Assal F.</b>	P16, P17, P40, P44, P54	<b>Carela J.</b>	P29, P61
<b>Al Assal R.</b>	P16, P17, P40, P44, P54	<b>Castrogiovanni P.</b>	P68
<b>Albergati F.</b>	P7, P50	<b>Caufriez M.</b>	O15
<b>Alici B.</b>	P9, P62	<b>Cawello W.</b>	R2
<b>Allona-Almagro A.</b>	R25	<b>Cayan S.</b>	P14
<b>Alm P.</b>	O13, D8	<b>Chaikin D.C.</b>	P13
<b>Altay B.</b>	P22	<b>Chamorro F.G.</b>	O30
<b>Althof S.E.</b>	O1	<b>Chatteraj S.C.</b>	O5
<b>Amosov F.R.</b>	P46	<b>Chaudhari</b>	P27
<b>Anafarta K.</b>	P17	<b>Chen J.</b>	O20
<b>Andereeben R.</b>	D30, P23	<b>Chibisov M.P.</b>	P24
<b>Andersson K.E.</b>	R14, O13, D8	<b>Chitale S.</b>	P27
<b>Andresen R.</b>	P23, D35	<b>Chkhotua A.B.</b>	P53, P59
<b>Arena F.</b>	D34	<b>Chogogidze T.</b>	P37
<b>Arger P.</b>	D18	<b>Christ G.J.</b>	O10
<b>Ari G.</b>	D4	<b>Christodulou K.</b>	D16, P18, P43
<b>Asvestis C.</b>	P1	<b>Cimen K.</b>	P14, P63
<b>Austoni E.</b>	R23, D38, P30, P36, P38	<b>Cipollone G.</b>	D34
<b>Aydos K.</b>	D17	<b>Claes P.</b>	P6
<b>Baltaci S.</b>	D17	<b>Coglitore M.T.</b>	P71
<b>Banzer D.</b>	O23	<b>Colocoglu Z.</b>	P22
<b>Baracho A.L.</b>	P16, P44	<b>Colombo F.</b>	D38, P30, P36, P38
<b>Barbieri L.</b>	P6, D15, D27, D29	<b>Colubev Y.</b>	P39
<b>Basile Fasolo C.</b>	P68	<b>Constantinides C.</b>	O28, P2, P3, P10, P31, P47, P70
<b>Becker A.J.</b>	O3	<b>Constantinides E.</b>	P2, P10, P31, P47, P70
<b>Beckmann R.</b>	O9	<b>Coppard N.J.</b>	D12
<b>Beduk Y.</b>	D17	<b>Cormio L.</b>	D31, P33
<b>Beekman R.</b>	O12	<b>Cornud F.</b>	P57
<b>Bell C.R.W.</b>	D7	<b>Cortellini P.</b>	P40, P54
<b>Benoit G.</b>	D10, P5	<b>Corsianai Cunico S.</b>	D36, P51
<b>Bernabe J.</b>	O7, D6	<b>Costa P.</b>	D9
<b>Berne J.M.</b>	P29, P61	<b>Curri S.B.</b>	P29, P61
<b>Bilene C.</b>	O15	<b>Cuzin B.</b>	P68
<b>Blanchet P.</b>	D10	<b>Da Pozzo G.P.</b>	O15
<b>Bondil P.</b>	R10, O27, D21, D22	<b>Da Pozzo L.</b>	R2
<b>Borzhievsky A.</b>	P39	<b>Dayley J.T.</b>	P14
<b>Botturi A.</b>	D36	<b>Darjinoff J.J.</b>	P13
<b>Bourli A.</b>	P10, P31, P47, P70	<b>Dashwood M.R.</b>	O30
<b>Braf Z.</b>	O20	<b>Daures J.P.</b>	O5
<b>Broderick G.A.</b>	O11, D9, D18, P13	<b>Davenport A.</b>	O27
<b>Burgos Rodriquez R.</b>	P58	<b>De la Fuente R.B.</b>	O20
		<b>DeLuca V.</b>	P24

## AUTHORS INDEX

<b>De Mayer J.M.</b>	P27	<b>Gondre M.</b>	O10
<b>De Thomas R.</b>	P53, P59	<b>Gong C.</b>	O11
<b>Degni M.</b>	P37	<b>Gonzalvo A.</b>	P29, P61
<b>Delaere K.P.J.</b>	O10	<b>Gougis S.</b>	D3
<b>Delmas V.</b>	O27	<b>Graziottin A.</b>	D29, D43
<b>Destouni E.</b>	E56, P65	<b>Guazzoni G.</b>	O6, D15, D27, D29, D37, D43
<b>Diaz A.</b>	P42, P55		D42, D44, P11, P60
<b>Diaz K.</b>	P42	<b>Guillaux G.</b>	O8
<b>Djordjevic B.</b>	P67	<b>Gupta S.</b>	O8
<b>Dordevic M.</b>	P41	<b>Gutierrez Calzada J.L.</b>	P58
<b>Droupy S.</b>	D10, P5	<b>Gvozdev M.</b>	P24
<b>Dubernard J.M.</b>	D23	<b>Hadfield J.</b>	P27
<b>Duckett J.</b>	D9	<b>Haensel S.M.</b>	D41
<b>Dunsmuir W.D.</b>	P8	<b>Hansen F.</b>	O25
<b>Duran R.</b>	O30	<b>Har-Shai Y.</b>	D32
<b>Ebbehøj J.</b>	R9	<b>Hattat H.</b>	P9, P62
<b>Edgren J.</b>	D31	<b>Hatzichristou D.</b>	R11
<b>Equez F.</b>	P55	<b>Hauck E.</b>	P21
<b>Engel A.</b>	D32	<b>Hauri D.</b>	O17
<b>Erder M.H.</b>	O1	<b>Heaton J.P.W.</b>	D1, D2
<b>Erdogru I.</b>	P14, P63	<b>Hedelin H.</b>	O29
<b>Ertekin C.</b>	P22	<b>Hedlund P.</b>	O13, D8
<b>Escribano G.</b>	O30	<b>Hernandez C.</b>	O30
<b>Fabra M.</b>	O21	<b>Hinrichs H.</b>	P21
<b>Fedel M.</b>	D30, P23	<b>Hoekstra H.J.</b>	O19
<b>Fenice O.</b>	D38, P30, P36, P38	<b>Hop W.C.J.</b>	P37
<b>Ferini-Strambi L.</b>	O18	<b>Hypolite J.A.</b>	D9
<b>Ferreira R.</b>	D42, D44	<b>Iannaccone S.</b>	O6
<b>Finberg J.P.M.</b>	D4	<b>Incrocci L.</b>	P37
<b>Frego E.</b>	P51	<b>Israilov S.</b>	D24, P12
<b>Galaup J.P.</b>	D23	<b>Jallous H.</b>	P71
<b>Galili Y.</b>	P12	<b>Janknegt R.</b>	P20
<b>Garrido V.</b>	P44	<b>Jara J.</b>	O30
<b>Ge S.P.</b>	D1, D2	<b>Jardin A.</b>	O7, D5, D10, P5
<b>Gekas A.</b>	P1	<b>Johanns A.</b>	O21
<b>Geneidi G.</b>	P45	<b>Jonas U.</b>	O3, D39, P21
<b>Gerhardus R.</b>	O9	<b>Jonker-Pool G.</b>	O19
<b>Gerstenberg T.</b>	O2, O25, D28	<b>Jünemann K.P.</b>	R20, O8
<b>Giambroni L.</b>	D36, P51	<b>Kadioglu A.</b>	P14, P63
<b>Gil P.</b>	P29, P61	<b>Kagawa S.</b>	D25, P4
<b>Gingell C.</b>	R22	<b>Kalaitzis C.</b>	D30, P23
<b>Giraldi A.</b>	O10	<b>Kallan K.T.H.</b>	D41
<b>Giuliano F.</b>	R5, O7, O16, D3, D5, D6, D10, P5	<b>Kameya Y.</b>	P66
		<b>Kanfer I.</b>	O5
<b>Glick H.A.</b>	O1	<b>Kapatsi P.</b>	P1
<b>Gofton W.T.</b>	D1	<b>Kardosh C.B.</b>	P17
<b>Goldstein I.</b>	R12	<b>Kaver I.</b>	O20
<b>Golzarian J.</b>	D19	<b>Kawanishi Y.</b>	D25, P4